Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Explore this paper's citation graph
Summary
Infectious SARS-CoV-2 B.1.617.2 spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes, which is believed to spread faster than the other versions.
- Type
- preprint
- Published
- 2021-05-27
- Cited by
- 137
- References
- 60
- Access
- Open access
- OpenAlex
- https://openalex.org/W3164250739
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:235244262
Keywords
Virology, Spike Protein, Antibody, Monoclonal antibody, Epitope
References
- Efficient generation of human IgA monoclonal antibodies.
- Nextstrain: real-time tracking of pathogen evolution
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- Distinct conformational states of SARS-CoV-2 spike protein
- Syncytia formation by SARS‐CoV‐2‐infected cells
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
- Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
- Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
- Sex differences in the decline of neutralizing antibodies to SARS-CoV-2
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Cited by
- Accuracy of rapid point-of-care antibody test in patients with suspected or confirmed COVID-19
- SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
- A Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2 Variants.
- The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants
- Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
- COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
- Second wave of COVID-19 in India could be predicted with genomic surveillance of SARS-CoV-2 variants coupled with epidemiological data: A tool for future
- Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
- Antibody and B cell responses to SARS-CoV-2 infection and vaccination
- Divergent trajectories of antiviral memory after SARS-CoV-2 infection
- SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough
- Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern.
- SnapShot: SARS-CoV-2 antibodies
- Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India
- Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin
- BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
- N‐terminal domain of SARS CoV‐2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals
- SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough
- SARS-CoV-2 Delta variant pathogenesis and host response in Syrian hamsters
- Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without
Related papers
- Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope ELDKWA and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines against HIV-1
- Mapping of 10 epitopes on bovine herpesvirus type 1 glycoproteins gI and gIII.
- Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
- Quantitative Assessment of Masking of Neutralization Epitopes in HIV-1
- Chicken Antibodies: A Tool to Avoid Interference by Human Anti-Mouse Antibodies in ELISA After In Vivo Treatment With Murine Monoclonal Antibodies
- Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- Commercial immunoglobulin products now contain neutralising antibodies against SARS-CoV-2 spike antibody which are detectable in patient serum
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies